Interview with Deepak Khanna, Senior Vice President and Managing Director UK,…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Address: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, United Kingdom
Tel: +44 (0) 1992 467272
Merck Sharp & Dohme Limited (MSD) is the UK subsidiary of Merck & Co., Inc., of Whitehouse Station, New Jersey, USA, a leading research-based pharmaceutical company that discovers, develops, manufactures and markets a wide range of innovative pharmaceutical products to improve human health.
MSD has committed substantial investment to research and manufacturing in the UK because of the unrivalled scientific excellence and skills base available here. It has two sites in the UK: headquarters and pharmaceutical research and development laboratories in Hoddesdon, Hertfordshire; and manufacturing at Cramlington in Northumberland.
x MSD employs approximately 1,400 people in the UK
x MSD’s UK headquarters are located in Hoddesdon, Hertfordshire, where the company’s sales and marketing, medical services, market research and administration functions are situated
x Pharmaceutical research and development is also located at Hoddesdon. Recent investment has established Hoddesdon as a global centre of expertise in chemistry, to serve Merck & Co., Inc.’s organic and synthetic chemistry needs
x The pharmaceutical manufacturing and supply centre in Cramlington, Northumberland, continues to lead the industry and the Merck & Co., Inc. organisation in productivity, delivering important medicines to the Merck network
x There are additional administrative offices in both London and Stockley Park
x MSD has played a key role in the development of five of Merck & Co., Inc.’s products 16 medicines are manufactured in the UK by MSD
x The UK turnover in 2007 was £382 million
x The UK Sales Force is made up of around 500 field-based employees
MSD’s mission is to provide superior medicines which enhance patients’ quality of life. Of Merck & Co., Inc.’s most popular medicines, five have been discovered and 16 are manufactured by MSD in the UK.
MSD’s product portfolio covers a range of key therapy areas including atherosclerosis and cardiovascular disease, diabetes, infectious diseases, neuroscience and ophthalmology, respiratory, bone, arthritic conditions, and vaccines.
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE,…
Thembalath Ramachandran, chairman and managing director of one of the UK’s fastest growing generics manufacturers, Bristol Laboratories, describes why he chose to relocate from India to start his business, the…
Philip Lews Williams, managing director of the UK affiliate of French ophthalmology specialist Théa, describes the evolution of the company’s engagement in the UK and his strategy for taking on…
Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential…
Heading the Life Sciences strategy for Scotland’s main economic development agency Scottish Enterprise, Julia Brown recalls some of the region’s unique features making it an ideal place for life Sciences…
As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back…
Ian Shott, co-founder and CEO of Arcinova, tells the story of how he established a speciality CMO on an historic site and discloses his plans to revolutionise small molecule manufacturing…
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Having recently joined the UK operations of AstraZeneca after a varied international career, Laurent Abuaf shares his vision of the UK as a life sciences reference market and his take…
Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive…
Promoting the UK’s capital in times of Brexit, Laura Citron, CEO at London & Partners, the international promotional agency of the Mayor of London, stresses the critical importance life sciences…
Erik Nordkamp, managing director of Pfizer UK, has been confirmed as the new president of the Association of the British Pharmaceutical Industry (ABPI). With UK life sciences still uncertain as…
See our Cookie Privacy Policy Here